REGN · Regeneron Pharmaceuticals, Inc.
$761.852026-05-17Sector: Healthcare; Industry: Biotechnology; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Bull
$2409
+216.3% vs market
Base · active
$1519
+99.4% vs market
Bear
$1144
+50.1% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($1144 · $2409) Analysts Range ($700 · $1057) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $16.1B | — | 100.3% | 13.4% | $14.0B | −$3.5B | $10.5B | 3.9% | — | 63.1% | $22.1B | $75.12 | — |
| 2022.Q4 | $12.2B | -24.3% | 79.7% | 10.7% | $8.7B | −$303MM | $8.4B | 5.7% | — | 37.3% | $24.3B | $40.36 | — |
| 2023.Q4 | $13.1B | 7.8% | 59.8% | 5.9% | $7.4B | −$2.0B | $5.4B | 5.6% | — | 28.9% | $26.8B | $36.78 | — |
| 2024.Q4 | $14.2B | 8.3% | 50.6% | 7.7% | $6.6B | −$3.0B | $3.6B | 6.3% | — | 21.5% | $35.0B | $41.05 | — |
| 2025.Q4 | $14.3B | 1.0% | 45.0% | 13.9% | $5.6B | −$2.9B | $2.7B | 6.0% | — | 15.0% | $38.8B | $41.91 | 12.7 |
| italics below = DCF projection · 10yr Rev CAGR: 6.3% |
| 2026.Q4 | $15.7B | +9.5% | 81.0% | 14.5% | $10.9B | −$3.2B | $7.7B | 6.1% | $7.2B | 26.9% | $42.0B | $31.16 | 24.4 |
| 2027.Q4 | $17.3B | +10.3% | 74.8% | 15.1% | $11.0B | −$4.0B | $7.0B | 6.4% | $6.2B | 25.0% | $46.0B | $34.85 | 21.9 |
| 2028.Q4 | $18.7B | +7.9% | 68.5% | 15.7% | $10.8B | −$3.5B | $7.3B | 6.6% | $6.0B | 22.6% | $49.5B | $38.12 | 20.0 |
| 2029.Q4 | $20.2B | +7.9% | 62.3% | 16.3% | $10.5B | −$3.2B | $7.3B | 6.9% | $5.7B | 20.6% | $52.7B | $41.67 | 18.3 |
| 2030.Q4 | $21.2B | +5.3% | 49.7% | 16.9% | $8.8B | −$2.3B | $6.5B | 7.1% | $4.7B | 16.3% | $55.0B | $45.27 | 16.8 |
|
| Term. Yr+ | $27.6B | 4.1% | 49.7% | 20.0% | $11.0B | −$2.8B | $8.2B | 8.6% | $90.6B | 16.2% | — | — | — |
Active scenario IV: $1519 (+99.4% vs market)